Keeping Track: A Quintet Of Novel Approvals

The latest drug development news and highlights from our US FDA Performance Tracker. 

Keeping Track Feature image

Here's your news in brief: It was by far the US Food and Drug Administration's busiest week of the year for novel drug approvals with five such products getting the green light from the agency: Genentech Inc.'s Rozlytrek (entrectinib), Celgene Corp.'s Inrebic (fedratinib), the Global Alliance for TB Drug Development's pretomanid, Harmony Biosciences LLC’s Wakix (pitolisant) and AbbVie Inc.’s Rinvoq (upadacitinib).

The Center for Drug Evaluation and Research's novel drug approval count has now jumped to 23 for the year.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>